At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed non-small cell lung cancer
- ✓Surgically determined stage IIIA or IIIB disease
- ✓Measurable and evaluable disease
- ✓Patients with N3 or T4 status must be evaluated and deemed potentially resectable after induction chemotherapy and radiation therapy
- ✕No malignant pleural effusion except for effusion visible only on CT scan and deemed too small to tap
- ✕No pericardial effusion
- ✕No small or mixed small cell/non-small cell lung cancer
- ✕No massive lesions requiring radiation to the entire lung
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Trial of Neoadjuvant Paclitaxel, Carboplatin and OSI-774 (Tarceva) With Concurrent Accelerated Hyperfractionation Radiation Followed by Maintenance Therapy With OSI-774 for Stage III Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating carboplatin, Erlotinib, and 3 other interventions for Lung Cancer. Completed, enrolled 32 participants across 1 site.
Detailed Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving erlotinib, paclitaxel, and carboplatin together with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase I/II trial is studying the best dose of erlotinib and the side effects of erlotinib, paclitaxel, and carboplatin when given together with radiation therapy and to see how well they work in treating patients who are undergoing surgery for stage III non-small cell lung cancer.
Study Details
Timeline
Interventions
AUC2 weekly x 3 weeks
Daily
50mg/m2/weekly x 3 weeks
conventional surgery
150 cGy bid